We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Aspen Pharmacare (APNHY) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Aspen Pharmacare (APNHY - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Aspen Pharmacare is one of 916 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Aspen Pharmacare is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for APNHY's full-year earnings has moved 7.6% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, APNHY has gained about 46.3% so far this year. Meanwhile, the Medical sector has returned an average of 8.6% on a year-to-date basis. This means that Aspen Pharmacare is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Aveanna Healthcare (AVAH - Free Report) . The stock has returned 61.1% year-to-date.
For Aveanna Healthcare, the consensus EPS estimate for the current year has increased 14.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Aspen Pharmacare belongs to the Medical - Generic Drugs industry, a group that includes 12 individual companies and currently sits at #88 in the Zacks Industry Rank. On average, stocks in this group have gained 15.9% this year, meaning that APNHY is performing better in terms of year-to-date returns.
On the other hand, Aveanna Healthcare belongs to the Medical - Outpatient and Home Healthcare industry. This 14-stock industry is currently ranked #103. The industry has moved +29.1% year to date.
Investors with an interest in Medical stocks should continue to track Aspen Pharmacare and Aveanna Healthcare. These stocks will be looking to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Aspen Pharmacare (APNHY) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Aspen Pharmacare (APNHY - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Aspen Pharmacare is one of 916 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Aspen Pharmacare is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for APNHY's full-year earnings has moved 7.6% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, APNHY has gained about 46.3% so far this year. Meanwhile, the Medical sector has returned an average of 8.6% on a year-to-date basis. This means that Aspen Pharmacare is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Aveanna Healthcare (AVAH - Free Report) . The stock has returned 61.1% year-to-date.
For Aveanna Healthcare, the consensus EPS estimate for the current year has increased 14.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Aspen Pharmacare belongs to the Medical - Generic Drugs industry, a group that includes 12 individual companies and currently sits at #88 in the Zacks Industry Rank. On average, stocks in this group have gained 15.9% this year, meaning that APNHY is performing better in terms of year-to-date returns.
On the other hand, Aveanna Healthcare belongs to the Medical - Outpatient and Home Healthcare industry. This 14-stock industry is currently ranked #103. The industry has moved +29.1% year to date.
Investors with an interest in Medical stocks should continue to track Aspen Pharmacare and Aveanna Healthcare. These stocks will be looking to continue their solid performance.